Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22683313 | 0.81 | ADORA2A (0.48) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL19974599 | 0.74 | ADORA1 (0.40) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL19978975 | 0.71 | ADORA2A (0.41) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL19974410 | 0.69 | ADORA2A (0.64) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL6838477 | 0.65 | ADORA2A (0.74) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL19978907 | 0.64 | ADORA1 (0.38) | ADORA2AHRH2HTR5AADORA3ADORA1 | |
| SCHEMBL19975005 | 0.64 | ADORA2A (0.46) | ADORA2AADORA3 | |
| SCHEMBL27087637 | 0.64 | LMNA (0.45) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL19974564 | 0.64 | ADORA2A (0.58) | ADORA2AADORA3ADORA1ADORA2BALOX15 | |
| SCHEMBL19974415 | 0.64 | ADORA2A (0.47) | ADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512860-A1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB Pharma Inc. (CA) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018049534-A1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |